Prostate cancer incidence, mortality and survival trends in Estonia, 1995–2014

References

• Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138:1388–1400.
   PubMed Web of Science ®Google Scholar
• Bray F, Lortet-Tieulent J, Ferlay J, et al. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46:3040–3052.
   PubMed Web of Science ®Google Scholar
• Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–1092.
   PubMed Web of Science ®Google Scholar
• Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test. JAMA. 2014;311:1143–1149.
   PubMed Web of Science ®Google Scholar
• Gondos A, Krilaviciute A, Smailyte G, et al. Cancer surveillance using registry data: results and recommendations for the Lithuanian national prostate cancer early detection programme. Eur J Cancer. 2015;51:1630–1637.
   PubMed Web of Science ®Google Scholar
• Innos K, Baburin A, Aareleid T. Cancer patient survival in Estonia 1995-2009: time trends and data quality. Cancer Epidemiol. 2014;38:253–258.
   PubMed Web of Science ®Google Scholar
• Mathers CD, Fat DM, Inoue M, et al. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ. 2005;83:171–177.
   PubMed Web of Science ®Google Scholar
• Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note no. 10. Bethesda, MD: National Cancer Institute, End Results Evaluation Section; 1959.
   Google Scholar
• Brenner H, Gefeller O, Hakulinen T. Period analysis for “up-to-date” cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer. 2004;40:326–335.
   PubMed Web of Science ®Google Scholar
• Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40:2307–2316.
   PubMed Web of Science ®Google Scholar
• Dickman PV, Coviello H, Hills M. Estimating and modelling relative survival. STATA J. 2015;15:186–215.
   Web of Science ®Google Scholar
• Zimmermann M-L, Innos K, Härmaorg P, et al. Vähihaigestumus 2009–2013 ja 20 aasta trendid Eestis [Cancer incidence in Estonia 2009–2013 and 20-year temporal trends]. Eesti Arst. 2017;96:11–20. (Estonian with English summary).
   Google Scholar
• Adami H-O. The prostate cancer pseudo-epidemic. Acta Oncol. 2010;49:298–304.
   PubMed Web of Science ®Google Scholar
• Kvåle R, Auvinen A, Adami H-O, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007;99:1881–1887.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Briers E, et al. EAU-ESTRO-SIAG Guidelines on Prostate Cancer. European Association of Urology. 2016. Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2016.pdf
   Google Scholar
• Littlejohns TJ, Travis RC, Key TJ, et al. Lifestyle factors and prostate-specific antigen (PSA) testing in UK Biobank: implications for epidemiological research. Cancer Epidemiol. 2016;45:40–46.
   PubMed Web of Science ®Google Scholar
• Tekkel M, Veideman T. Health behavior among estonian adult population. Tallinn: National Institute for Health Development. 2016. Available from: https://intra.tai.ee//images/prints/documents/149069399613_Eesti_taiskasvanud_rahvastiku_tervisekaitumise_uuring_2016.pdf
   Google Scholar
• Neppl-Huber C, Zappa M, Coebergh JW, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol. 2012;23:1325–1334.
   PubMed Web of Science ®Google Scholar
• Forman D, Bray F, Brewster DH, et al. editors. Cancer Incidence in Five Continents, Vol. X (Electronic Version). Lyon: International Agency for Research on Cancer, 2013 [cited 2017 Mar 15]. Available from: http://ci5.iarc.fr
   Google Scholar
• Parkin DM, Muir CS, Whelan SL, et al. editors. Cancer Incidence in Five Continents, Vol. VI. Lyon: International Agency for Research on Cancer; 1992.
   Google Scholar
• Engholm G, Ferlay J, Christensen N, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7.3 (08.07.2016). Association of the Nordic Cancer Registries. Danish Cancer Society; 2017 [cited 2017 Mar 17]. Available from http://www.ancr.nu
   Google Scholar
• Bratt O, Berglund A, Adolfsson J, et al. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden. Scand J Urol Nephrol. 2010;44:384–390.
   PubMed Web of Science ®Google Scholar
• Nderitu P, Van Hemelrijck M, Ashworth M, et al. Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested? BMJ Open. 2016;6:e011356.
   PubMed Web of Science ®Google Scholar
• Salinas CA, Tsodikov A, Ishak-Howard M, et al. Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014;11:317–323.
   PubMed Web of Science ®Google Scholar
• Outzen M, Brasso K, Martinussen N, et al. Prostate cancer in Denmark 1978-2009-trends in incidence and mortality. Acta Oncol. 2013;52:831–836.
   PubMed Web of Science ®Google Scholar
• Feuer EJ, Merrill R, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer-part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999;91:1025–1032.
   PubMedGoogle Scholar
• Fall K, Strömberg F, Rosell J, et al. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008;42:352–357.
   PubMed Web of Science ®Google Scholar
• Seikkula HA, Kaippia AJ, Rantanen ME, et al. Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA. Acta Oncol. 2017;56:971–977.
   PubMed Web of Science ®Google Scholar
• Trama A, Foschi R, Larrañaga N, et al. Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: results from the EUROCARE-5 study. Eur J Cancer. 2015;51:2206–2216.
   PubMed Web of Science ®Google Scholar
• Innos K, Lang K, Pärna K, et al. Age-specific cancer survival in Estonia: recent trends and data quality. Clin Epidemiol. 2015;7:355–362.
   PubMed Web of Science ®Google Scholar
• Cancer Registry of Norway. Cancer in Norway 2012: Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2014.
   Google Scholar
• Winter A, Sirri E, Jansen L, et al. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions? BJU Int. 2017;119:550–559.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. Statistical bulletin: cancer survival by stage at diagnosis for England (experimental statistics): Adults diagnosed 2012, 2013 and 2014 and followed up to 2015. 2017 [cited 2017 Apr 10]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalbystageatdiagnosisforenglandexperimentalstatistics/adultsdiagnosed20122013and2014andfollowedupto2015#survival-by-stage
   Google Scholar